PARACELSUS MEDIZINISCHE PRIVATUNIVERSITAT SALZBURG - PRIVATSTIFTUNG

Their core work

Paracelsus Medical University (PMU) is a private medical university in Salzburg, Austria, focused on clinical research and advanced cell-based therapies. Their H2020 work centers on translational medicine — moving laboratory findings into patient treatments, particularly in regenerative medicine (heart therapies, urinary continence) and rare disease research. They bring clinical trial expertise and cell therapy manufacturing knowledge to European research consortia, contributing medical-grade research infrastructure and patient access in Austria.

What they specialise in

How they've shifted over time

PMU's early H2020 work (2016-2017) was tightly focused on hands-on regenerative medicine: heart cell therapies, muscle precursor cells, and advanced cell manufacturing processes for urinary incontinence treatment. From 2019 onward, the focus broadened significantly toward systemic health challenges — rare disease data infrastructure (FAIR, omics, patient empowerment) and palliative care for Parkinson's. This shift suggests a move from bench-to-bedside cell therapy work toward broader translational medicine and patient-centered research frameworks.

PMU is evolving from a cell therapy specialist toward a broader translational medicine partner with growing strength in rare disease data ecosystems and patient-oriented research design.

How they like to work

PMU participates exclusively as a partner — never as coordinator — which positions them as a reliable consortium contributor rather than a project driver. With 177 unique partners across 35 countries in just 5 projects, they consistently join large-scale European consortia (EJP RD alone is a massive multi-partner programme). This means they are experienced at working within complex, multi-national project structures and can integrate smoothly into large teams.

Despite only 5 projects, PMU has built a remarkably wide network of 177 unique partners across 35 countries, driven largely by participation in major pan-European programmes. Their reach spans nearly all EU member states and associated countries.

What sets them apart

PMU combines the agility of a private medical university with deep clinical trial infrastructure — they can run phase IIb studies and manufacture cell therapy products under regulated conditions. Their dual expertise in hands-on regenerative medicine and rare disease research networks makes them an unusual bridge between laboratory cell science and Europe-wide patient data ecosystems. For consortium builders, they offer Austrian clinical site access plus proven experience in both small focused trials and large pan-European programmes.

Highlights from their portfolio

• PACE
  Largest funded project (EUR 687,250) — a multicenter phase IIb clinical study using placenta-derived stromal cells, demonstrating capacity for advanced clinical trial execution.
• EJP RD
  Part of the European Joint Programme on Rare Diseases, one of the largest health research coordination efforts in H2020, connecting PMU to a vast rare disease research network.
• MUSIC
  Longest-running project (2017-2022) combining muscle precursor cell research with xenofree manufacturing — a direct pipeline from lab to clinical application for urinary incontinence.